Heart Failure Therapy: Innovation
Examples of innovation in treating heart failures are SensiVest, Sacubitril/Valsartan Entresto and CardioMEMS.
SensiVest for heart failure
- Researchers for Sensible Medical have developed an innovative heart failure treatment device called the SensiVest.
- The SensiVest can be worn by the patient over their clothes, and the device uses a radar technology "originally developed by the military to scan inside the body and monitor fluid buildup in the lungs."
- The device saves patients the stress and time of waiting to report their symptoms to a doctor because patients can simply wear the vest. The vest scans the patient for about three minutes and then transmits the information wirelessly to the doctor who can conduct further assessments, recommend dietary changes and intervene with medication.
- According to a study published in August 2017, "wearing the SensiVest daily for three months decreased hospital readmission by 87 percent."
- Sacubitril/Valsartan Entresto is an innovative drug used for the treatment of heart failure.
- The drug has recently been approved by both the NICE (National Institute Health and Clinical Effectiveness) and the SMC (Scottish Medicine Agency).
- The drug works in two different ways. First, it boosts the body’s natural resistance against heart failure and second, it blocks the body’s natural system that harms the heart. "It combines two drugs: a new one called Sacubitril and Valsartan, a drug that has been used for some time in heart failure."
- The mixture of these two drugs has "improved both death rates and hospitalization in heart failure by up to 20% in a clinical trial."
- Some cons of the drugs include weight gain, vomiting, coughing, and sudden back pain.
- Some pros include significant improvement in daily functions and energy levels.
- CardioMEM is a monitoring system also known as wireless pulmonary artery haemodynamic monitoring.
- The innovative device works by measuring the pressures in patients' pulmonary artery, "which will rise before a patient notices a deterioration in their heart failure symptoms, e.g. breathlessness or swelling."
- The device passed through examinations in the USA. A lot of patients who were NYHA III were fitted with the device and then compared with a group of patients who were not. The results over 18 months showed a reduction in hospital admissions of over 37%.
- The device enables the clinician to better manage heart failure symptoms of patients, and it helps to avoid deterioration and admission into the hospital. Patients also indicated a greater quality of life and reduction in deaths.
- Some cons of the device include minor anxiety over the procedure and understanding that it is a permanent device.
- Some pros include fewer CHF-related hospitalizations.
To provide the three examples of innovation in treating heart failure, we started by reviewing industrial articles, market reports, articles, white papers and many more. We have reviewed sources such as CNBC, healthcare weekly and many more. The team has provided three innovation in treating heart failure. These examples were selected based on the impact the treatment has on heart failure patients.